Sandrine Kraemer

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

Jean‐Yves Pierga, Thierry Petit, T. Delozier et al. · The Lancet Oncology · 2012 · 153 citations

Medicine, Oncology, Pharmacology +16

Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study

Jaafar Bennouna, Christophe Borg, Jean‐Pierre Delord et al. · Clinical Colorectal Cancer · 2011 · 31 citations

Medicine, Oncology, Pharmacology +11

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment

Kristell Marzin, Gunther Kretschmar, Doreen Luedtke et al. · The Journal of Clinical Pharmacology · 2017 · 30 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib

Teresa Morán, Ramón Palmero, Mariano Provencio et al. · Lung Cancer · 2017 · 24 citations

Medicine, Oncology, Pharmacology +13